|
|
| Line 13: |
Line 13: |
|
| |
|
| ===Pharmacokinetics=== | | ===Pharmacokinetics=== |
| {| class="wikitable" border="1" width="55%" style="text-align:center"
| | <table style="background: cellspacing="0px" align="" cellpadding="0px" width="50%"> |
| |-
| | <tr> |
| ! colspan="4" align="center"| EGFR Inhibitor [[Pharmacokinetics]] Comparison at Equivalent Dosages <ref>PMID:16609030</ref><ref>PMID:17482782</ref><ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref>
| | <td style="width:auto; vertical-align:top;border-width:0px; border-style:inset"> |
| |-
| | <div style="overflow:auto; height:100%; width: 100%"> |
| ! Parameter
| | {{:Tyrosine Kinase Inhibitor Pharmacokinetics}} |
| ! [[Erlotinib]] <br/>(Tarceva)
| | </div> |
| ! [[Gefitinib]] <br/>(Iressa)
| | </td> |
| ! [[Lapatinib]] <br/>(Tykerb)
| | </tr> |
| |-
| | </table> |
| ! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
| |
| ! 2.0
| |
| ! 5.4
| |
| ! 4
| |
| |-
| |
| ! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
| |
| ! 69.6
| |
| ! 130
| |
| ! 115
| |
| |-
| |
| ! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
| |
| ! 99
| |
| ! 59
| |
| ! Variable
| |
| |-
| |
| ! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)
| |
| ! 93
| |
| ! 90
| |
| ! 99
| |
| |-
| |
| ! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
| |
| ! 9.4
| |
| ! 26.9
| |
| ! 9.6
| |
| |-
| |
| ! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
| |
| ! 20577
| |
| ! 3850
| |
| ! 1429
| |
| |-
| |
| ! Typical Dosage (mg)
| |
| ! 150
| |
| ! 250
| |
| ! 100
| |
| |-
| |
| ! Metabolism
| |
| ! Hepatic - (CYP3A4)
| |
| ! Hepatic - (CYP3A4)
| |
| ! Hepatic - (CYP3A4)
| |
| |}
| |
|
| |
|
| ===References=== | | ===References=== |